Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologiesWould meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyondAll-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("H ...